Phase 2 Trial to Assess Keytruda Combination Therapy in Ovarian Cancer

Phase 2 Trial to Assess Keytruda Combination Therapy in Ovarian Cancer
A Phase 2 clinical trial will assess for the first time whether the combination of the immunotherapy drug Keytruda (pembrolizumab) with two other drugs that have already been approved for ovarian cancer — Avastin (bevacizumab) and Cytoxan (cyclophosphamide) — can benefit patients with ovarian, fallopian tube, or peritoneal cancer. The study is also the first analyze patients' microbiomes to identify possible correlations between bacteria composition and tumor responses. Keytruda has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma, non-small cell lung cancers, and recurrent head and neck squamous cell carcinoma. In ovarian cancer, however, the small number of patients who received the drug as a single therapy showed only modest responses. But the study's principal investigator, Emese Zsiros, MD, PhD, believes there is a strong rationale supporting the addition of Keytruda to the two ovarian cancer drugs, and that this combination may show a much broader effect than Keytruda therapy alone. "Our biggest hope is that by trying these three drugs in combination, we can significantly extend the lives of patients with recurrent ovarian cancer. We also hope to minimize the side effects associated with chemotherapy drugs, and to markedly improve the quality of our patients' lives," Zsiros, assistant professor of oncology at Buffalo, New York's Roswell Park Cancer Institute's Department of Gynecologic Oncology and Center for Immunotherapy, said in a press release. "We will be looking at potential biomarkers that will tell us who can most benefit from this therapy combination and to better understand how cancer cells and immune cells c
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *